Categories
Change Password!
Reset Password!
This study was carried to explore bone mineral density (BMD), trabecular bone score (TBS), and bone turnover in patients with GERD not previously exposed to proton pump inhibitors (PPIs) vs. healthy age-matched controls.
In people with gastroesophageal
reflux disease (GERD), short-term use of pantoprazole therapy did not affect
the bone parameters and was found to be safe for the skeleton.
This study was carried to explore
bone mineral density (BMD), trabecular bone score (TBS), and bone turnover in
patients with GERD not previously exposed to proton pump inhibitors (PPIs) vs.
healthy age-matched controls. Furthermore, it aimed to determine whether these
parameters were influenced by therapy with the PPI pantoprazole for three
months.
In
total, 17 GERD subjects (5 females/12 males) not previously exposed to PPI, and
17 age- and gender-matched healthy controls were recruited. With the help of
dual X-ray absorptiometry, the BMD at the femoral neck, lumbar spine, total
hip, and TBS at the lumbar spine (the marker of bone microarchitecture) were
estimated. The markers of calcium homeostasis and bone turnover, and gastric
hormones were examined. The same parameters were estimated following three
months of therapy with the PPI pantoprazole.
The GERD people (age 32–73 years)
demonstrated a considerably reduced TBS at baseline when compared to controls
(1.31± 0.11 vs. 1.43 ± 0.07). The total hip and femoral neck BMD were reduced
(though not significant) in GERD people when compared to controls. C-terminal
telopeptide (CTX) was non-significantly elevated in GERD subjects at baseline.
Following three months, alterations in CTX, BMD, and TBS did not differ between
the groups.
PPI-naive GERD patients were found
to have a bone impairment that may translate to greater fracture risk. No
profound alterations in TBS, BMD, or bone turnover markers were noted after
three months of therapy with pantoprazole, indicating that short-term
pantoprazole therapy is safe in a skeletal health context.
Bone Reports
Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?
Kristin M. Aasarod et al.
Comments (0)